Edition:
India

Zynerba Pharmaceuticals Inc (ZYNE.OQ)

ZYNE.OQ on NASDAQ Stock Exchange Global Market

20.98USD
28 Apr 2017
Change (% chg)

$-0.01 (-0.05%)
Prev Close
$20.99
Open
$20.91
Day's High
$21.34
Day's Low
$20.64
Volume
74,689
Avg. Vol
125,353
52-wk High
$25.95
52-wk Low
$6.02

Select another date:

Mon, Mar 27 2017

BRIEF-Zynerba Pharmaceuticals qtrly loss per share $0.71

* Zynerba - top-line results from fab-c exploratory phase 2 clinical trial in pediatric patients with fragile x syndrome expected in q3 of 2017

BRIEF-Zynerba Pharmaceuticals completes enrollment for ZYN002 in two phase 2 clinical trials for epilepsy and osteoarthritis

* Zynerba Pharmaceuticals announces completion of enrollment for ZYN002 in two Phase 2 clinical trials for epilepsy and osteoarthritis Source text for Eikon: Further company coverage:

BRIEF-Zynerba Pharmaceuticals says estimates that as of Dec. 31 cash and cash equivalents were about $31 mln

* Zynerba Pharmaceuticals Inc - estimates that as of December 31, 2016 cash and cash equivalents were approximately $31.0 million Source text - http://bit.ly/2jp373S Further company coverage:

BRIEF-Zynerba Pharmaceuticals announces proposed public offering of common stock

* Zynerba Pharmaceuticals announces proposed public offering of common stock

BRIEF-Zynerba Pharmaceuticals posts Q3 loss per share of $0.67

* Zynerba Pharma - believes available funds sufficient to develop five phase 3 ready programs, sufficient to fund operations & capital requirements into 2018

BRIEF-Zynerba Pharmaceuticals initiates Star 2 open-label extension clinical trial for ZYN002 CBD gel

* Zynerba Pharmaceuticals Inc says enrollment in Star 1 is continuing and plan to report top line results in first half of 2017

Select another date:

More From Around the Web